Compare GGB & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GGB | CYTK |
|---|---|---|
| Founded | 1901 | 1997 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.6B |
| IPO Year | 2000 | 2004 |
| Metric | GGB | CYTK |
|---|---|---|
| Price | $3.72 | $60.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 18 |
| Target Price | $4.60 | ★ $86.00 |
| AVG Volume (30 Days) | ★ 24.0M | 1.6M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $4.94 | $37.53 |
| Revenue Next Year | $4.36 | $214.81 |
| P/E Ratio | $13.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.27 | $29.31 |
| 52 Week High | $4.66 | $70.98 |
| Indicator | GGB | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 31.02 | 38.75 |
| Support Level | $2.84 | $59.23 |
| Resistance Level | $3.73 | $65.93 |
| Average True Range (ATR) | 0.11 | 2.59 |
| MACD | -0.05 | -0.74 |
| Stochastic Oscillator | 8.92 | 9.49 |
Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutors, mechanical construction bars, and reinforced steel locks. The company's geographical segment includes Brazil Operations; North America Operations; South America Operations as well as Special Steel Operations. It derives the majority of its revenue from the Brazil Operations segment.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.